Innovative gene and cell therapies have the potential to treat previously incurable serious diseases. SaxoCell® is bringing strong German players from this field together to develop and produce these ‘living drugs’ for safe, effective and affordable treatment.
SaxoCell channels regional innovations towards the design, manu-facture and application of specialized therapeutic cells. Its vision: To establish a unique cell and gene therapy value chain and industry in Saxony by bundling comprehensive cell and gene therapy research expertise with industrial R&D expertise – and bringing it together with novel technologies including artificial intelligence, automation, Omics technologies and others.
As a cluster of leading research institutes and medical facilities which extends across the Free State of Saxony in Eastern Germany, SaxoCell has found a strong partner in Leipzig and its institutions:
The City of Leipzig has provided support from SaxoCell’s inception and is committed to the consortium’s success
The Fraunhofer Institute for Cell Therapy and Immunology IZI plays a valuable role within SaxoCell due to its expertise in the field of cell and gene therapy R&D and its specialized infrastructure (e.g. clean-room facilities)
University Hospital Leipzig is a SaxoCell partner, and the city’s university offers excellent basic, applied and clinical research in areas relevant to SaxoCell’s goals
Last but not least, critical infrastructure such as the Halle-Leipzig airport with its high-performance logistics providers make the city an attractive member of the SaxoCell consortium.
“As part of the SaxoCell consortium here in Leipzig, we are very excited to be able to contribute to the initiative’s success through our competences in the field of cell technologies,”
says SaxoCell speaker Prof. Ulrike Köhl from the Fraunhofer IZI. Her colleague Prof. Uwe Platzbecker from the University Hospital Leipzig adds: “In addition to Leipzig, SaxoCell has strong partners in Dresden and Chemnitz, as well as in other locations across the Free State of Saxony.”
SaxoCell enables the novel cell and gene therapies or ATMPs (Advanced Therapy Medicinal Products) which its partners develop to quickly reach patients with previously hard-to-treat serious diseases – thus providing them with new hope for the future.
Established in 2021, SaxoCell is one of the winners of the innovation competition “Clusters4Future” of the German Federal Ministry of Education and Research. The consortium has set itself ambitious goals, e.g. to integrate more partners nationwide, to facilitate access to funding, to increase the visibility of institutional and corporate R&D activities, and eventually to help establish a strong and vibrant cell and gene therapy industry in Saxony. Learn more at www.saxocell.de
A relatively small metropolis in Germany’s Free State of Saxony – a dynamic hub for the life science industry? What was just a vision 20 years ago has become a reality for the city of Leipzig, which from October 24-26 co-hosted BIO-Europe, Europe’s largest annual biotech partnering event.
In cancer therapy, physicians need to assess huge amounts of complex medical data. KAIT is a digital platform which uses extensive data analysis to evaluate this information so doctors can identify the best treatment option for each individual patient.